Refine by
Lymphoma Equipment & Supplies
178 equipment items found
Manufactured by:Veracyte, Inc. based inSouth San Francisco, CALIFORNIA (USA)
LymphMark (Lymphoma) – We are developing this lymphoma subtyping test as a companion diagnostic for Acerta Pharma and AstraZeneca’s acalabrutinib (Calquence®). In April 2021, we announced that the first patient has been enrolled and randomized in Acerta Pharma’s Phase 3 ESCALADE trial, which uses the investigational LymphMark test to ...
Manufactured by:Takeda Pharmaceutical Company Limited based inChuo-ku, JAPAN
Bortezomib (brand name: Velcade) is a treatment for multiple myeloma (a cancer of the plasma cells) and mantle cell lymphoma (a cancer of the lymph ...
Manufactured by:Antengene Corporation Limited based inChangning District, CHINA
Diffuse large B-cell lymphoma (DLBCL) is one of the most common types of non-Hodgkin lymphoma (NHL) in adults and a highly heterogeneous malignancy in both clinical manifestations and prognosis. DLBCL accounts for 30%-40% of all NHL cases, and over 40% in most Asian ...
Manufactured by:Eutilex Co.,Ltd. based inSeoul, SOUTH KOREA
MVR CAR-T can be used against HLA-DR positive cancer, as well as B cell malignancy. The epitopes recognized by HLA-DR are not shed or internalized, enabling stable binding to human lymphoma cells. MVR CAR-T can also be used in patients who relapse after CD19 CAR-T treatment. Reduction of cytokine secretion due to selective killing of tumor ...
Manufactured by:TriStar Technology Group LLC based inWashington, DISTRICT OF COLUMBIA (USA)
Molecular Data: No; Approx. # of Donors: 72; Follow Up Data: No; Cores per Donor: 2; Core Size: 1mm; Approx. # of Cores *: 144; TA number: TA3089; Suitable for (IHC or RNA-ISH): IHC; Suitable for CODEX/GeoMx/CosMx: ...
Manufactured by:Medax Srl based inSan Possidonio (MO), ITALY
Patented rectangular shaped cannula. 4 mm wide flat biopsy sample. Ultrasharp stylet tip clearly visible with ultrasound guidance. Adjustable penetration depth 12/22 mm. Centimeter markings. Ergonomic handle. Easy sample retrieval and release. Sterilized by ETO, shelf life 5 ...
Manufactured by:Takeda Pharmaceutical Company Limited based inChuo-ku, JAPAN
Brentuximab vedotin (brand name: Adcetris) is a treatment for post-transplant consolidation, relapsed or refractory Hodgkin lymphoma (cancer of the lymphatic system distinguished by the presence of CD30-positive Reed-Sternberg cells), and systemic anaplastic large cell lymphoma (a type of aggressive T-cell ...
Manufactured by:Creative Peptides based inNew York, NEW YORK (USA)
Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) or/and peripheral T-cell lymphoma (PTCL) in patients who have received at least one prior systemic therapy. These indications are based on response rate. Clinical benefit such as improvement in overall survival has not been ...
Manufactured by:Caprico Biotechnologies, Inc. (CBI) based inNorcross, GEORGIA (US) (USA)
The L243 reacts with human HLA-DR antigen which is expressed on B lymphocytes, monocytes, macrophages, activated T lymphocytes, activated natural killer (NK) lymphocytes, and human progenitor cells. HLA-DR is also present on thymic epithelium, B lymphocyte dependent areas of spleen and lymph node, and B cell ...
Manufactured by:Abologix based inGeneva, SWITZERLAND
JAM-C is expressed by certain lymphocytes and prominently localises to tight junctions of endotelial cells. In many lymphoma cells, JAM-C is ...
Manufactured by:TC BioPharm based inHolytown, UNITED KINGDOM
TCB003 is an allogeneic CAR-T product using engineered GDTs from healthy donors and specifically targets CD19, which is highly expressed on a number of B cell malignancies. These malignancies, such as acute lymphoblastic Leukaemia (ALL) or diffuse large B cell lymphoma (DLBCL) arise when B cells replicate uncontrollably within the bone marrow, before progressing to the ...
Manufactured by:ALL Chemistry Inc. based inMarlton, NEW JERSEY (USA)
TJ191 is a selective anti-cancer agent, targeting low TβRIII-expressing malignant T-cell leukemia/lymphoma ...
Manufactured by:Sana Biotechnology based inSeattle, WASHINGTON (USA)
Oncology: Non-Hodgkin lymphoma (NHL), Acute lymphoblastic leukemia (ALL), Chronic lymphocytic leukemia ...
Manufactured by:Sana Biotechnology based inSeattle, WASHINGTON (USA)
Oncology; Non-Hodgkin lymphoma (NHL), Acute lymphoblastic leukemia (ALL), Chronic lymphocytic leukemia ...
Manufactured by:Sana Biotechnology based inSeattle, WASHINGTON (USA)
Oncology: Non-Hodgkin lymphoma (NHL), Acute lymphoblastic leukemia (ALL), Chronic lymphocytic leukemia ...
Manufactured by:Sana Biotechnology based inSeattle, WASHINGTON (USA)
Oncology: Non-Hodgkin lymphoma (NHL), Acute lymphoblastic leukemia (ALL), Chronic lymphocytic leukemia ...
Manufactured by:Affimed GmbH based inHeidelberg, GERMANY
Lighting the way with clinical results: we are creating success with monotherapies and combination therapies. AFM13, a first-in-class ICE (innate cell engager) molecule targeting patients with CD30-positive lymphomas,4 showed antitumor responses in a Phase 1/2 trial as a monotherapy in 15 patients with T-cell lymphomas and cutaneous involvement (44% ORR).5 When ...
Manufactured by:Beijing Challen Biotechnology Co., Ltd. based inDaxing District, CHINA
Testable items: Lymphocyte subpopulation detection, regulatory T cells, PD-1, expressed in most large granular lymphocytic leukemia (LGL), and also expressed in a small number of T cell ...
Manufactured by:MorphoSys AG based inPlanegg, GERMANY
It is therefore considered as a potential target for the treatment of B cell malignancies, such as non-Hodgkin’s lymphoma (NHL), including diffuse large B cell lymphoma (DLBCL), indolent lymphomas like follicular lymphoma (FL) and marginal zone lymphomas (MZL), as well as chronic lymphocytic leukemia (CLL). ...
Manufactured by:Enterome based inParis, FRANCE
The clinical rationale behind targeting these specific lineage cell markers is to induce the full depletion of malignant B lymphocytes enriched in indolent non-Hodgkin lymphoma (iNHL). EO2463 is being evaluated in a Phase 1/2 clinical trial as monotherapy and in combination with standard-of-care lenalidomide and/or rituximab for the treatment of iNHL (SIDNEY study, EONHL1-20). ...